{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:41:06Z","timestamp":1792536066925,"version":"4.5.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T00:00:00Z","timestamp":1781395200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002661","name":"Fund for Scientific Research","doi-asserted-by":"publisher","award":["F 5\/4\/150\/5 - SPD"],"award-info":[{"award-number":["F 5\/4\/150\/5 - SPD"]}],"id":[{"id":"10.13039\/501100002661","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.esmogo.2026.100372","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:00:19Z","timestamp":1784538019000},"page":"100372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"PB","title":["Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey"],"prefix":"10.1016","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1714-234X","authenticated-orcid":false,"given":"C.","family":"Bouchart","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2435-4757","authenticated-orcid":false,"given":"M.","family":"Delaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-6896","authenticated-orcid":false,"given":"I.","family":"Garajova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sa Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2026.100372_bib1","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S2468-1253(23)00207-8","article-title":"The immunological landscape in pancreatic ductal adenocarcinoma and overcoming resistance to immunotherapy","volume":"8","author":"Hilmi","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.esmogo.2026.100372_bib2","doi-asserted-by":"crossref","first-page":"768","DOI":"10.3390\/cancers15030768","article-title":"Combination, modulation and interplay of modern radiotherapy with the tumor microenvironment and targeted therapies in pancreatic cancer: which candidates to boost radiotherapy?","volume":"15","author":"Benkhaled","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100372_bib3","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/s41416-025-03274-0","article-title":"Favorable histo-molecular remodeling of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX followed by high-dose stereotactic body radiotherapy","volume":"134","author":"Bouchart","year":"2026","journal-title":"Br J Cancer"},{"key":"10.1016\/j.esmogo.2026.100372_bib4","doi-asserted-by":"crossref","first-page":"3634","DOI":"10.3390\/cancers15143634","article-title":"Overview of pancreatic cancer epidemiology in Europe and recommendations for screening in high-risk populations","volume":"15","author":"Partyka","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.esmogo.2026.100372_bib5","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920936093","article-title":"Novel strategies using modern radiotherapy to improve pancreatic cancer outcomes: toward a new standard?","volume":"12","author":"Bouchart","year":"2020","journal-title":"Ther Adv Med Oncol"},{"issue":"13","key":"10.1016\/j.esmogo.2026.100372_bib6","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.3390\/cancers16132423","article-title":"Total neoadjuvant therapy in localized pancreatic cancer: is more better?","volume":"16","author":"Saude-Conde","year":"2024","journal-title":"Cancers"},{"issue":"11","key":"10.1016\/j.esmogo.2026.100372_bib7","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.annonc.2023.08.009","article-title":"Pancreatic cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Conroy","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100372_bib10","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1097\/CEJ.0000000000000303","article-title":"Trends in net survival from pancreatic cancer in six European Latin countries: results from the SUDCAN population-based study","volume":"26","author":"Bouvier","year":"2017","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.esmogo.2026.100372_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12916-018-1120-9","article-title":"Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study","volume":"16","author":"Huang","year":"2018","journal-title":"BMC Med"},{"key":"10.1016\/j.esmogo.2026.100372_bib12","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1007\/s12029-015-9724-1","article-title":"A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs","volume":"46","author":"Carrato","year":"2015","journal-title":"J Gastrointest Cancer"},{"key":"10.1016\/j.esmogo.2026.100372_bib13","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1186\/s12885-023-11377-1","article-title":"Treatment sequences and prognostic\/predictive factors in metastatic pancreatic ductal adenocarcinoma: a real-world study in Europe","volume":"23","author":"Taieb","year":"2023","journal-title":"BMC Cancer"},{"issue":"16","key":"10.1016\/j.esmogo.2026.100372_bib14","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1200\/JCO.19.02274","article-title":"Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial","volume":"38","author":"Versteijne","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100372_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-023-11327-x","article-title":"Preoperative treatment with mFOLFIRINOX (or gemcitabine\/nab-paclitaxel) \u00b1 isotoxic high-dose SBRT (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomized multicentre phase II trial","volume":"23","author":"Bouchart","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100372_bib16","doi-asserted-by":"crossref","first-page":"W217","DOI":"10.2214\/AJR.18.19640","article-title":"Routine MRI with DWI sequences to detect liver metastases in patients with potentially resectable pancreatic ductal carcinoma and normal liver CT: a prospective multicenter study","volume":"211","author":"Marion-Audibert","year":"2018","journal-title":"AJR Am J Roentgenol"},{"issue":"15","key":"10.1016\/j.esmogo.2026.100372_bib17","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.3390\/cancers15153816","article-title":"Evaluation of nutritional status and the impact of nutritional treatment in patients with pancreatic cancer","volume":"15","author":"Mekal","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.esmogo.2026.100372_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.clinre.2023.102153","article-title":"Nutrition support in pancreatic cancer: an expert statement on practical implementation of French guidelines","volume":"47","author":"Taieb","year":"2023","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.esmogo.2026.100372_bib19","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12957-022-02803-y","article-title":"The role of staging laparoscopy in pancreatic adenocarcinoma and its effect on survival","volume":"20","author":"Jambor","year":"2022","journal-title":"World J Surg Oncol"},{"issue":"5","key":"10.1016\/j.esmogo.2026.100372_bib20","first-page":"580","article-title":"Impact of a multidisciplinary team approach on managing focal pancreatic lesions: a single tertiary center experience","volume":"36","author":"Francisse","year":"2023","journal-title":"Ann Gastroenterol"},{"key":"10.1016\/j.esmogo.2026.100372_bib21","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","article-title":"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017","volume":"18","author":"Isaji","year":"2018","journal-title":"Pancreatology"},{"issue":"8","key":"10.1016\/j.esmogo.2026.100372_bib22","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.annonc.2024.05.003","article-title":"Letter to the editor: Radiation therapy for locally advanced pancreatic adenocarcinoma: a therapeutic option which should not be forgotten","volume":"35","author":"Huguet","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100372_bib23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1001\/jama.2016.4324","article-title":"Effect of chemoradiotherapy vs chemotherapy on survival in patients with locally advanced pancreatic cancer: the LAP07 randomized clinical trial","volume":"315","author":"Hammel","year":"2016","journal-title":"JAMA"},{"issue":"16_suppl","key":"10.1016\/j.esmogo.2026.100372_bib24","doi-asserted-by":"crossref","first-page":"4008","DOI":"10.1200\/JCO.2022.40.16_suppl.4008","article-title":"Randomized phase III trial of induction chemotherapy followed by chemoradiotherapy or chemotherapy alone for nonresectable locally advanced pancreatic cancer: first results of the CONKO-007 trial","volume":"40","author":"Fietkau","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.esmogo.2026.100372_bib25","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","article-title":"Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable pancreatic cancer: A021501 randomized phase II trial","volume":"8","author":"Katz","year":"2022","journal-title":"JAMA Oncol"},{"issue":"S2","key":"10.1016\/j.esmogo.2026.100372_bib26","article-title":"LBA62: preoperative modified FOLFIRINOX with or without chemoradiation in borderline resectable pancreatic cancer (BRPC): PANDAS\/PRODIGE 44 phase II trial","volume":"35","author":"Lambert","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmogo.2026.100372_bib27","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1200\/JCO.21.02233","article-title":"Neoadjuvant chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer: long-term results of the Dutch randomized PREOPANC trial","volume":"40","author":"Versteijne","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.esmogo.2026.100372_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.10.084","article-title":"LBA83: Neoadjuvant chemotherapy with FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy for borderline resectable and resectable pancreatic cancer (PREOPANC-2): a multicenter randomized controlled trial","volume":"34","author":"Groot Koerkamp","year":"2023","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.esmogo.2026.100372_bib29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1186\/s12885-025-15041-8","article-title":"TORPEDO: a randomized phase II study of stereotactic body radiotherapy for inoperable non-metastasized pancreatic adenocarcinoma","volume":"25","author":"Stas","year":"2025","journal-title":"BMC Cancer"},{"key":"10.1016\/j.esmogo.2026.100372_bib32","article-title":"Treatment planning for MR-guided SBRT of upper abdominal tumors on a 1.5T MR-Linac: a global consensus protocol","volume":"47","author":"Grimbergen","year":"2024","journal-title":"Clin Transl Radiat Oncol"},{"key":"10.1016\/j.esmogo.2026.100372_bib33","article-title":"Facilitating 1.5T MR-Linac adoption: workflow strategies and practical tips","volume":"16","author":"Michel","year":"2025","journal-title":"J Appl Clin Med Phys"},{"issue":"10522","key":"10.1016\/j.esmogo.2026.100372_bib34","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1016\/S0140-6736(25)01685-X","article-title":"Preoperative mFOLFIRINOX versus PAXG for stage I\u2013III resectable and borderline resectable pancreatic ductal adenocarcinoma (PACT-21 CASSANDRA): results of the first randomisation analysis of a randomised, open-label, 2\u00d72 factorial phase 3 trial","volume":"406","author":"Reni","year":"2026","journal-title":"Lancet"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000725?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819826000725?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:37:38Z","timestamp":1792535858000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819826000725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":30,"alternative-id":["S2949819826000725"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100372","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current practices and challenges in the management of nonmetastatic pancreatic adenocarcinoma: results of an EORTC survey","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2026.100372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100372"}}